Literature DB >> 3462001

A transcriptional enhancer with specificity for erythroid cells is located in the long terminal repeat of the Friend murine leukemia virus.

Z Bösze, H J Thiesen, P Charnay.   

Abstract

We investigated the ability of the U3 region of the long terminal repeats (LTR) of the Friend murine leukemia virus (Fr-MuLV) and Moloney murine leukemia virus (Mo-MuLV) to promote transcription in a variety of human cell lines. Our analysis reveals the presence of a transcriptional enhancer with specificity for erythroid cells in the U3 region of the Fr-MuLV. This constitutes the first example of an enhancer with such a property. Analysis of the Mo-MuLV enhancer suggests that it is active at least in erythroid and lymphoid cells and has thus a less restricted specificity than the Fr-MuLV enhancer. The different tissue specificities of the two enhancers correlate with the different tissue selectivities and pathogenic properties of the two viruses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462001      PMCID: PMC1166987          DOI: 10.1002/j.1460-2075.1986.tb04404.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

1.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

2.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

3.  Induction of erythroid differentiation in the human leukaemia cell line K562.

Authors:  L C Andersson; M Jokinen; C G Gahmberg
Journal:  Nature       Date:  1979-03-22       Impact factor: 49.962

4.  HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression.

Authors:  P Martin; T Papayannopoulou
Journal:  Science       Date:  1982-06-11       Impact factor: 47.728

5.  Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker.

Authors:  S I Drew; P I Terasaki; R J Billing; O J Bergh; J Minowada; E Klein
Journal:  Blood       Date:  1977-05       Impact factor: 22.113

6.  Delineation of transcriptional control signals within the Moloney murine sarcoma virus long terminal repeat.

Authors:  B J Graves; R N Eisenman; S L McKnight
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

7.  Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia.

Authors:  E Klein; H Ben-Bassat; H Neumann; P Ralph; J Zeuthen; A Polliack; F Vánky
Journal:  Int J Cancer       Date:  1976-10-15       Impact factor: 7.396

8.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

9.  Absence of thymus-derived lymphocyte markers in myelogenous leukemia (Ph1+) cell line K-562.

Authors:  C B Lozzio; B B Lozzio; W K Yang; A T Ichiki; E G Bamberger
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

10.  Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells.

Authors:  M S Neuberger
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  29 in total

1.  Differential DNA binding of nuclear proteins to a long terminal repeat region of the MCF13 and Akv murine leukemia viruses.

Authors:  F K Yoshimura; J Tupper; K Diem
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  A DNA element responsible for the different tissue specificities of Friend and Moloney retroviral enhancers.

Authors:  H J Thiesen; Z Bösze; L Henry; P Charnay
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

3.  Enhancer sequences of a retroviral vector determine expression of a gene in multipotent hematopoietic progenitors and committed erythroid cells.

Authors:  C A Holland; P Anklesaria; M A Sakakeeny; J S Greenberger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Nucleotide sequence of LTR-gag region of Rous sarcoma virus adapted to semi-permissive host.

Authors:  V I Kashuba; S V Zubak; V M Kavsan; A V Rynditch; I Hlozanek
Journal:  Nucleic Acids Res       Date:  1990-09-25       Impact factor: 16.971

5.  DNA-binding proteins that interact with the long terminal repeat of radiation leukemia virus.

Authors:  I Gorska-Flipot; P Jolicoeur
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

6.  Identification of genetic determinants responsible for the rapid immunosuppressive activity and the low leukemogenic potential of a variant of Friend leukemia virus, FIS-2.

Authors:  H Y Dai; G I Troseth; M Gunleksrud; T Bruland; L A Solberg; H Aarset; L I Kristiansen; A Dalen
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Mapping of functional regions of murine retrovirus long terminal repeat enhancers: enhancer domains interact and are not independent in their contributions to enhancer activity.

Authors:  T Hollon; F K Yoshimura
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

8.  Distinct segments within the enhancer region collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses.

Authors:  E Golemis; Y Li; T N Fredrickson; J W Hartley; N Hopkins
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

9.  Different relative expression from two murine leukemia virus long terminal repeats in unintegrated transfected DNA and in integrated retroviral vector proviruses.

Authors:  K Paludan; H Y Dai; M Duch; P Jørgensen; N O Kjeldgaard; F S Pedersen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Members of the GATA family of transcription factors bind to the U3 region of Cas-Br-E and graffi retroviruses and transactivate their expression.

Authors:  C Barat; E Rassart
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.